Multiple sclerosis activist Christina Applegate recently announced that her multiple sclerosis diagnosis was incorrect, based on new test results, Live Science writes. Why can this disease be difficult to identify?
Actress Christina Applegate was diagnosed with multiple sclerosis (MS) more than five years ago — but this week, she announced that a recent re-evaluation revealed she doesn’t have the condition after all. Following this revelation, she remained undiagnosed and told a podcast that she felt she was “back to square one, where I don’t know what’s happening to me”.
Applegate’s case is not entirely unique, although the diagnosis of multiple sclerosis has improved over the years. Studies provide varying estimates of the frequency with which MS is misdiagnosed, with rates ranging from 5% to over 40%, depending on the patient population and clinical setting. There is also some degree of underdiagnosis — cases where people with MS are not identified as having the disease.
So how difficult is it to identify MS and what does this mean for patients? Live Science spoke with experts about the current state of MS diagnosis and what improvements may come in the future.
“It’s also very important for doctors and patients to be aware that it’s not inappropriate to review a diagnosis — to make sure it’s correct,” Dr. Ari Green, chief of the Division of Neuroimmunology and Glial Biology at the University of California, San Francisco, told Live Science.
What is multiple sclerosis and what effects does it have on the body
Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the central nervous system, i.e. the brain and spinal cord. These attacks directly affect neurons and also target myelin—a fatty, insulating substance that coats the nerve fibers of neurons and helps them transmit signals effectively.
This damage leads to characteristic scarring of the nerve tissue and causes a range of symptoms, including vision problems, muscle weakness, tingling sensations, dizziness and bladder control problems. Patients with untreated and advanced MS may lose the ability to walk and stand or, in some cases, develop partial or complete paralysis.
These serious consequences are becoming rarer as treatments have improved significantly, Green said. Current treatments keep immune attacks in check and thus prevent further nerve damage.
Also read: An old hypothesis about the brain is called into question. What researchers found in a new study
“It’s gone from people getting severely and profoundly disabled after 10 or 20 years of illness, to now, after 30 or 40 years of illness, they’re only moderately disabled,” Green told Live Science.
The disease most often occurs between the ages of 20 and 40, although it can occur in any age group. An important point, Green emphasized, is that “the earlier people with MS start treatment, the better their long-term outcome.”
For this reason, it is important to diagnose MS effectively so that patients can begin essential treatment, said Dr. Yohance Allette, a neuroimmunologist and researcher at Penn State Health. “In this situation, you try to be as proactive as possible.”
Why multiple sclerosis is difficult to diagnose
However, there is no single infallible test that can reliably prove that a person has MS. “With multiple sclerosis, it all comes down to the key word ‘criteria,'” Allette said.
Multiple sclerosis experts have compiled a regularly updated list of criteria that reflect how features of multiple sclerosis manifest in lab tests, brain, optic nerve and spinal cord scans, and in patients’ symptoms. Green was among dozens of experts involved in the last update, which took place in 2024 and was published in 2025.
The first step in evaluating a patient is recognizing symptoms that might indicate multiple sclerosis.
These early symptoms — such as problems with balance, vision or bowel control — vary significantly from person to person and may not immediately raise suspicions that the patient has a neurological problem, Green said. However, how symptoms appear can be a clue: MS symptoms usually get worse for a day or a few days and then go away, he noted.
Once worrisome symptoms are reported, MRI scans of the brain and spinal cord are performed. The images can show signs of myelin damage, and neurologists analyze their shape, size and location. Lesions often occur near blood vessels, because that’s where immune cells enter the brain, Green pointed out.
Conditions that can be confused with multiple sclerosis
MRIs of the optic nerves can also reveal lesions associated with MS, and these examinations are emphasized in the latest diagnostic criteria, Allette noted. Electrophysiological tests, which assess nerve function, are also “extremely important because they provide completely different information than just seeing a lesion on an MRI,” Green said. Other signs of MS can be identified through lumbar punctures, which sample the fluid around the brain and spinal cord, which may contain proteins and inflammatory cells associated with MS.
In addition to collecting these clues, doctors must rule out diseases that resemble MS. These include neuromyelitis optica and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)—two other autoimmune conditions that affect the central nervous system. Both conditions are associated with distinctive and abnormal immune proteins, called autoantibodies, that attach to various parts of the nervous system; these specific antibodies are not seen in MS.
Other conditions—such as migraine, uncontrolled diabetes, or vascular disease—can also be accompanied by myelin damage. Therefore, it is essential that doctors identify the specific patterns associated with multiple sclerosis.
Neurologists specializing in multiple sclerosis have expertise in this task, while doctors in other neurological specialties may not know how to distinguish lesions associated with MS from those caused by other conditions, both Allette and Green noted.
“Ultimately, it’s a diagnosis of exclusion,” Allette said. “There are things you can rule out quickly,” while others take time to investigate in detail.
Conditions like MOGAD and neurosarcoidosis, an inflammatory condition sometimes confused with MS, can actually be made worse by MS drugs, Green noted. So if a patient’s MS flare-ups get worse after they start treatment, that could suggest something else is to blame, he said. But because there can be long intervals between exacerbations, doctors may need to monitor a patient for a period of time before worsening of their condition becomes apparent.
How certain is the diagnosis of multiple sclerosis
Given all the tools available, a patient can have reasonable confidence in their MS diagnosis, Green said.
“In general, there is currently a reasonable level of confidence in the diagnosis of MS,” he said. However, this confidence is at its maximum when the tools are in the hands of a specialist who adheres to the most up-to-date criteria, he pointed out. Test results require interpretation, and this is where uncertainty can arise.
As for Applegate’s situation, “to put it bluntly, I think this case came as a shock because we always expect that part of society to have quick access (to high-quality health care),” Allette said.
Also read: The virus present in 95% of people, associated with multiple sclerosis and cancer, can be blocked by a new antibody
For some patients, the road to accessing specialist MS care can be long, leading to mistakes and even misdiagnoses along the way. Applegate lived five years with an incorrect diagnosis, but “would it have been seven or eight years for someone who doesn’t have that access?” Allette speculated.
Without knowing the details of Applegate’s case, Allette and Green said it would be difficult to speculate on what led to the misdiagnosis. Applegate mentioned that his brain scans were re-evaluated using “new technology” but did not go into details.
Proteomic tests could improve the diagnosis of MS
Looking to the future of multiple sclerosis diagnosis, Green and Allette see emerging proteomic tests as very promising.
Such tests generate a profile of proteins and smaller fragments, called peptides, in a patient’s blood or cerebrospinal fluid. These can be designed to identify proteins involved in triggering underlying immune attacks as well as signs of nerve damage from MS, they explained.
These in-depth protein analyzes could help paint a more comprehensive picture of MS, which could ultimately help scientists “look at the whole system as a whole” to arrive at a definitive diagnosis, Allette said.
Will there ever be a single test for multiple sclerosis?
“Proteomics-based diagnostic tests for multiple sclerosis have not yet been approved,” Green said. Even with these future advances, he doubts there will ever be a simple, one-time test that can determine whether a patient has multiple sclerosis.
“I think it’s probably unlikely that things will ever be that simple,” he said.
Green, however, believes that over time scientists may reduce the number of tests needed to make a diagnosis, but argued that clinical evaluation by a neurologist will likely remain essential.
“I doubt there will ever be a test that completely replaces this,” he said, “at least in the foreseeable future.”